Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

Vaccine. 2011 Sep 23;29(42):7251-60. doi: 10.1016/j.vaccine.2011.07.020. Epub 2011 Jul 21.


Dengue. virus infection is the leading arboviral cause of disease worldwide. A vaccine is being developed based on the attenuated DEN-2 virus, DEN-2 PDK-53. In this review, we summarize the characteristics of the parent DEN-2 PDK-53 strain as well as the chimeric viruses containing the prM and E genes of DEN-1, DEN-3 or DEN-4 virus in the genetic backbone of the DEN-2 PDK-53 virus (termed DENVax). Tetravalent DENVax formulations containing cloned, fully sequenced isolates of the DEN-2 PDK-53 virus and the three chimeras have been evaluated for safety and efficacy in preclinical animal models. Based on the safety, immunogenicity and efficacy in preclinical studies, Phase 1 clinical testing of DENVax has been initiated.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials, Phase I as Topic
  • Dengue / immunology
  • Dengue / prevention & control*
  • Dengue Vaccines / administration & dosage*
  • Dengue Vaccines / adverse effects
  • Dengue Vaccines / immunology*
  • Dengue Virus / immunology
  • Dengue Virus / pathogenicity
  • Humans
  • Models, Animal
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / adverse effects
  • Vaccines, Attenuated / genetics
  • Vaccines, Attenuated / immunology
  • Vaccines, Synthetic / administration & dosage
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology


  • Dengue Vaccines
  • Vaccines, Attenuated
  • Vaccines, Synthetic